Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 | P08588 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | ACHE | P22303 | 3/20 | 0.48 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.43 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.42 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.41 |
| ▸ | HSP90AB1 | P08238 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.41 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30423191 | 0.88 | ADRB1 (0.50) | ADRB1KDM4EALDH1A1ACHEROCK2 | |
| SCHEMBL3509223 | 0.86 | CA12 (0.45) | ALDH1A1ACHESMN1; SMN2 | |
| SCHEMBL2792154 | 0.84 | ADRB1 (0.55) | ADRB1KDM4EALDH1A1ACHEROCK2 | |
| SCHEMBL20443370 | 0.84 | ADRB1 (0.52) | ADRB1KDM4EALDH1A1ACHEROCK2 | |
| Hydrochloric Acid SCHEMBL5368905 | 0.83 | ALDH1A1 (0.54) | ADRB1KDM4EALDH1A1ACHEROCK2 | |
| SCHEMBL20075911 | 0.83 | CA12 (0.49) | ACHEHRH3HRH4 | |
| SCHEMBL5987648 | 0.83 | KDM4E (0.49) | KDM4EALDH1A1HPGDSMN1; SMN2TAAR1 | |
| SCHEMBL905849 | 0.80 | ACHE (0.60) | ADRB1KDM4EALDH1A1ACHEHPGD | |
| SCHEMBL26748791 | 0.79 | ACHE (0.52) | ACHE | |
| SCHEMBL27013480 | 0.79 | CA12 (0.39) | ACHEHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3689868-A1 | TETRAHYDRONAPHTHALENE AND TETRAHYDROISOQUINOLINE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | Arvinas Operations, Inc. (US) | 2020-08-05 | — | — | EP | disclosed |
| EP-3660004-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | Arvinas Operations, Inc. (US) | 2020-06-03 | — | — | EP | disclosed |
| EP-1327630-B1 | NEW DERIVATIVES OF CYANO-ARYL (OR CYANOHETEROARYL)-CARBONYL-PIPERAZINYL-PYRIMIDINES, THEIR PREPARATION AND APPLICATION AS MEDICATION | ESTEVE LABOR DR (ES) | 2007-12-12 | — | — | EP | disclosed |
| US-7300937-B2 | Derivatives of cyano-aryl (or cyanoheteroaryl)-carbonyl-piperazinyl-pyrimidines, their preparation and application as medication | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-11-27 | — | — | US | disclosed |
| US-20040048872-A1 | New derivatives of cyano-aryl (or cyanoheteroaryl) -carbonyl- piperazinyl - pyrimidines, their preparation and application as medication | LABORATORIES DEL DR. ESTEVE, S.A. (ES) | 2004-03-11 | — | — | US | disclosed |
| EP-1327630-A1 | NEW DERIVATIVES OF CYANO-ARYL (OR CYANOHETEROARYL)-CARBONYL-PIPERAZINYL-PYRIMIDINES, THEIR PREPARATION AND APPLICATION AS MEDICATION | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2003-07-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040048872-A1 | New derivatives of cyano-aryl (or cyanoheteroaryl) -carbonyl- piperazinyl - pyrimidines, their preparation and application as medication | CBR3, CBR1, CNR1 | ADRB1 52/4885KDM4E 1472/4885ALDH1A1 304/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.